October 26 from 5:30 pm – 7:30 pm CDT
Grand Horizon Ballroom AB, Marriott Marquis Chicago | Developed and offered by UCB, Inc.
Program Description
Join our renowned expert speaker, Prof. Iain McInnes, as we piece together the SpA puzzle by unraveling the latest evidence on the inflammatory pathways that drive SpA pathobiology and how early control of inflammation can help improve patient outcomes.
This session will cover the following objectives:
- Describe the pathobiology of SpA and the associated patient burden of disease
- Explore the key cytokine pathways in axSpA and PsA, including the IL-17 superfamily, and their contribution to inflammation
- Evaluate the importance of early control of inflammation on improving outcomes in patients with SpA
Disclosures and COI:
Grants/research support, honoraria or consultant: AbbVie, Amgen, AnaptysBio, AstraZeneca, Bristol-Myers Squibb, Cabaletta, Causeway therapeutics, Compugen, Dextera, Eli Lilly, Gilead, Janssen, Montai, Moonlake, Novartis, Pfizer, Sanofi and UCB
Stock shareholder: Cabaletta, Causeway therapeutics, Compugen and Dextera
Speakers:
Presenter: Iain B. McInnes, CBE PhD FRCP FRSE FMedSci
Vice-Principal and Head of College of Medical, Veterinary and Life Sciences
Muirhead Chair of Medicine/Versus Arthritis Professor of Rheumatology
University of Glasgow
Presenter: Clive Liu, MD
University of Washington
Dermatology
Adjunct Faculty
Seattle, Washington